These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 21502428)

  • 21. Kaolin-based activated coagulation time measured by sonoclot in patients undergoing cardiopulmonary bypass.
    Ganter MT; Monn A; Tavakoli R; Klaghofer R; Zollinger A; Hofer CK
    J Cardiothorac Vasc Anesth; 2007 Aug; 21(4):524-8. PubMed ID: 17678778
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Whole blood coagulation analyzers.
    Health Devices; 1997 Aug; 26(8):296-332. PubMed ID: 9283920
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of aprotinin on activated clotting time, whole blood and plasma heparin measurements.
    Despotis GJ; Joist JH; Joiner-Maier D; Alsoufiev AL; Triantafillou AN; Goodnough LT; Santoro SA; Lappas DG
    Ann Thorac Surg; 1995 Jan; 59(1):106-11. PubMed ID: 7529483
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of celite and kaolin on activated clotting time in the presence of aprotinin: activated clotting time is reduced by binding of aprotinin to kaolin.
    Dietrich W; Jochum M
    J Thorac Cardiovasc Surg; 1995 Jan; 109(1):177-8. PubMed ID: 7529346
    [No Abstract]   [Full Text] [Related]  

  • 25. A comparison of activated coagulation time-based techniques for anticoagulation during cardiac surgery with cardiopulmonary bypass.
    Slight RD; Buell R; Nzewi OC; McClelland DB; Mankad PS
    J Cardiothorac Vasc Anesth; 2008 Feb; 22(1):47-52. PubMed ID: 18249330
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reproducibility and variability of activated clotting time measurements in the cardiac catheterization laboratory.
    Doherty TM; Shavelle RM; French WJ
    Catheter Cardiovasc Interv; 2005 Jul; 65(3):330-7. PubMed ID: 15864806
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of Point-of-Care Activated Clotting Time Methods in Different Clinical Settings in a Large Academic Medical Center.
    Korpi-Steiner NL; Walz JM; Schanzer A; Rao LV
    J Appl Lab Med; 2017 Nov; 2(3):356-366. PubMed ID: 33636841
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Measurement of the activated clotting time during cardiopulmonary bypass: differences between Hemotec ACT and Hemochron Jr apparatus.
    Svenmarker S; Appelblad M; Jansson E; Häggmark S
    Perfusion; 2004; 19(5):289-94. PubMed ID: 15506033
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reference values for kaolin-activated thromboelastography in healthy children.
    Chan KL; Summerhayes RG; Ignjatovic V; Horton SB; Monagle PT
    Anesth Analg; 2007 Dec; 105(6):1610-3, table of contents. PubMed ID: 18042858
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Noncitrated whole blood is optimal for evaluation of postinjury coagulopathy with point-of-care rapid thrombelastography.
    Kashuk JL; Moore EE; Le T; Lawrence J; Pezold M; Johnson JL; Cothren CC; Biffl WL; Barnett C; Sabel A
    J Surg Res; 2009 Sep; 156(1):133-8. PubMed ID: 19577246
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Factor Xa-activated whole blood clotting time (Xa-ACT) for bedside monitoring of dalteparin anticoagulation during haemodialysis.
    Frank RD; Brandenburg VM; Lanzmich R; Floege J
    Nephrol Dial Transplant; 2004 Jun; 19(6):1552-8. PubMed ID: 15034159
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Guidelines for certification of Activated clotting time (ACT) according to the EN ISO 22870 standards].
    Lasne D; Bauters A; Le Querrec A; Bourdin C; Voisin S; ;
    Ann Biol Clin (Paris); 2015; 73(2):225-54. PubMed ID: 25847747
    [TBL] [Abstract][Full Text] [Related]  

  • 33. When we "act" on ACT levels: activated clotting time measurements to guide heparin administration during and after interventional procedures.
    Klein LW; Agarwal JB
    Cathet Cardiovasc Diagn; 1996 Feb; 37(2):154-7. PubMed ID: 8808071
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Does a delay in performing an activated clotting (ACT) test really matter? A study in nonheparinized blood and a single ACT machine.
    Philip BM; Brock-Utne JG; Lemmens HJ; Jaffe RA; Shuttleworth PE
    J Extra Corpor Technol; 2008 Sep; 40(3):193-5. PubMed ID: 18853832
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Predictive performance of three methods of activated clotting time measurement in neonatal ECMO patients.
    Seay RE; Uden DL; Kriesmer PJ; Payne NR
    ASAIO J; 1993; 39(1):39-42. PubMed ID: 8439678
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interinstitutional comparison of bedside blood glucose monitoring program characteristics, accuracy performance, and quality control documentation: a College of American Pathologists Q-Probes study of bedside blood glucose monitoring performed in 226 small hospitals.
    Novis DA; Jones BA
    Arch Pathol Lab Med; 1998 Jun; 122(6):495-502. PubMed ID: 9625416
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [The "activated coagulation time (ACT)": two simple screening methods for evaluating coagulation disorders in dogs].
    Glaus T; Hudak-Glaus D; Hoeptner C; Arnold P; Lutz H
    Schweiz Arch Tierheilkd; 1996; 138(11):532-6. PubMed ID: 9026910
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [How much dosage of heparin do you administer? The relationship between heparin dosage and activated coagulation time (ACT) value during cardiovascular surgery: a multi center investigations].
    Shibasaki M; Nakajima Y; Kojima A; Kitagawa H; Tanimoto K; Mizobe T
    Masui; 2010 Apr; 59(4):535-9. PubMed ID: 20420155
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of point-of-care tests for diagnosis of disseminated intravascular coagulation in dogs admitted to an intensive care unit.
    Bateman SW; Mathews KA; Abrams-Ogg AC; Lumsden JH; Johnstone IB; Hillers TK
    J Am Vet Med Assoc; 1999 Sep; 215(6):805-10. PubMed ID: 10496132
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of a novel kallikrein inhibitor on hemostatic activation in vitro.
    Tanaka KA; Szlam F; Katori N; Vega JD; Levy JH
    Thromb Res; 2004; 113(5):333-9. PubMed ID: 15183046
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.